• B2C sales up 38% quarter-on-quarter, now 46% of total sales
• Total revenue up 19% year-on-year, cash receipts down 2%
• Funded for growth with NAB loan facility increased to $5.2 million

ECS Botanics Holdings Ltd (ASX: ECS), a leading medicinal cannabis company, has reissued its Q3 FY25 report to correct an error in the Financial Update section. The company reported continued rapid growth in its B2C business, with Q3 sales of $2.2 million, up 38% on the prior quarter, and now representing 46% of total sales. Total quarterly revenue was $4.8 million, a 1% increase on the prior quarter and a 19% increase on the prior corresponding period. Cash receipts of $4.3 million were down 9% quarter-on-quarter and 2% year-on-year, as the company focused on growing its B2C sales. ECS has onboarded 540 prescribers since July 2024 and is on track to exceed 700 within 12 months of launching its B2C brands. After the end of the quarter, ECS successfully increased its corporate loan facility with the National Australia Bank (NAB) from $3.2 million to $5.2 million, strengthening its working capital position and offering greater flexibility to support the launch of the Terphogz product line. The company's outdoor harvest has been of high quality, and the addition of new protective cropping enclosures has delivered a significant boost to product yield and quality, supporting the growing domestic sales pipeline and rising global demand.

ECS expects to demonstrate its ability to leverage its low-cost operating model with increased scale and yields to drive cashflow and profitability over the year ahead.

The company is excited by the new export opportunities that its partnership with Terphogz will unlock, along with the potential to further diversify its revenue streams. ECS plans to continue delivering sustainable growth and positive cash flow as it transitions to a more balanced B2C and B2B model.